Metadherin mRNA Expression in Bladder Cancer

Assiut University

Status: Unknown

Conditions: Bladder Cancer

Treatments: Diagnostic Test: Metadherin

Study type: Observational

Funder types: Other

Identifiers

NCT04286672

MmBC

Details and patient eligibility

About

The study aims to study alterations of MTDH gene expression in the serum of bladder cancer patients compared to control group to evaluate its role as a marker for diagnosis.

,to compare the diagnostic accuracy of MTDH with the previously used marker Bladder Cancer-Specific Antigen-1 (BLCA-1 in the serum of bladder cancer patients .

and to study correlation between expression of the metadherin gene and serum level of BLCA-1, and clinical and histopathological staging in patients with bladder cancer

Full description

Urinary bladder cancer (BC) is the ninth most common cancer worldwide. It is the fifth most common malignancy in males and seventeenth most common in females.

In Egypt, bladder cancer represents a massive health burden where it is one of the commonest cancers representing 6.9% in both sexes and 10.7% among men. Its distribution is 8.8% in lower Egypt, 14.2% in middle Egypt and 12.6% in upper Egypt.Almost 50% of patients will experience recurrence of their disease within 4 years of their initial diagnosis.The prognosis of bladder cancer is poor as a result of highly invasive properties of tumour cells.

The optimal treatment selection depends on early diagnosis as well as accurate staging and grading.Currently there is a need for new molecular bio markers that can help clinicians to identify patients requiring early, aggressive treatment.

Metadherin (MTDH) is an oncogene known as Astrocytic elevated gene-1(AEG-1).It was firstly identified in 2002 at fetal astrocytes of persons exposed to HIV-1 and then known as a vital oncogene mediating carcinogenesis,prognosis,invasion and cancer metastasis. AEG-1 expression is raised in bladder cancer tissues relative to normal tissues, and serves as a poor prognostic factor.

Enrollment: 70 estimated patients

Sex: All

Ages: 30 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Males and females.
• 30-80 years old.
• patients with bladder cancer not receiving any treatment

Exclusion criteria

1. patients taking chemotherapy or radiotherapy.
2. History of other malignancy.
3. History of autoimmune diseases.

Trial design

70 participants in 2 patient groups

Group 1:

Description:

• 35 bladder cancer patients diagnosed by biopsy before treatment.

Treatment:

Diagnostic Test: Metadherin

Group 2:

Description:

35 apparently healthy individuals who were matched by age and sex .

Treatment:

Diagnostic Test: Metadherin